News
QS Pharma receives approval from European Medicines Agency for commercial manufacture
QS Pharma, a Quotient Clinical business, is now approved to manufacture medicinal products for the US, Europe and Japan.
6 / 52 articles displayed
-
-
Acquisition
Quotient Clinical announces second US acquisition: QS Pharma
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired QS Pharma, the contract development and manufacturing organisation (CDMO), based near Philadelphia, US, from Charles River Laboratories International, Inc.
-
Acquisition
Quotient Clinical expands into USA through acquisition of SeaView Research, the specialist clinical pharmacology business
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired SeaView Research.
-
News
Quotient’s CCO Simon Lee elected as Secretary of European CRO Federation (EUCROF)
Quotient Sciences, the innovative provider of early phase drug development services, is pleased to announce that Chief Compliance Officer, Simon Lee, has been elected as Secretary of the European CRO Federation (“EUCROF”).
-
Awards
Quotient Clinical wins a BVCA Management Team of the Year Award
Quotient Sciences, the unique and innovative provider of drug development services, today announced it has received a British Private Equity & Venture Capital Association (BVCA) Management Team Award.
-
Growth
Quotient Clinical Expands Data Sciences Capability
Quotient Sciences, the Translational Pharmaceutics® company, a leading provider of early stage and specialist drug development services, today announced the expansion of its Data Sciences function with relocation to a larger office, staying in Edinburgh.